Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stereotaxis, Inc. Common Stock (NY:STXS)

0.9000 -0.1300 (-12.62%)
Official Closing Price Updated: 4:10 PM EST, Nov 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Stereotaxis, Inc. Common Stock

< Previous 1 2 3 Next >
Premarket Movers: Wednesday's US Open Gainers and Losers ↗
Via Chartmill
News headline image
What Stereotaxis (STXS) Said on Its Q3 Earnings Call ↗
Stereotaxis (NYSEAMERICAN:STXS) reported a 20% increase in third-quarter revenue as early sales of its GenesisX robotic system and Synchrony operating room technology helped offset continuing catheter... 
Via MarketBeat
Topics Earnings
News headline image
Stereotaxis (STXS) Q3 2026 Earnings Call Transcript ↗
Supply constraints and new financing shape the next phase for robotic catheter growth. 
Via The Motley Fool
Topics Earnings
Stereotaxis Inc (NYSEARCA:STXS) Slides 6% After Q1 Revenue Miss Despite Narrower-Than-Expected Loss ↗
Via Chartmill
STEREOTAXIS INC (NYSEARCA:STXS) Posts Narrower-Than-Expected Q4 Loss Despite Revenue Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Stereotaxis Earnings Preview ↗
 
Via Benzinga
After-Hours Stock Movers: KPTI Rises 140%, STAK Falls 51.5% After US Close ↗
Via Chartmill
News headline image
Stereotaxis (STXS) Q2 2026 Earnings Call Transcript ↗
MAGiC catheter adoption accelerates with 12 U.S. sites now performing procedures. 
Via The Motley Fool
Topics Earnings
News headline image
Stereotaxis Q2 Earnings Call Highlights ↗
Stereotaxis (NYSEAMERICAN:STXS) reported second-quarter 2026 revenue of $7.7 million, as growth in sales of its robotic catheter portfolio helped lift recurring revenue to a multiyear high despite... 
Via MarketBeat
Topics Earnings
Unusual volume stocks in Monday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased... 
Via Benzinga
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Stereotaxis Q1 Earnings Call Highlights ↗
Stereotaxis (NYSEAMERICAN:STXS) said its first-quarter results did not yet reflect what management described as a major commercial transition driven by new regulatory approvals, new catheter products... 
Via MarketBeat
Topics Earnings
News headline image
Robotic Revolution in the Electrophysiology Lab: FDA Clears Stereotaxis Synchrony System
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Stereotaxis Secures FDA Clearance for Synchrony™ System, Completing Its Vision for the Robotic "Digital Cockpit"
ST. LOUIS — April 6, 2026 — Stereotaxis (NYSE: STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias and other endovascular procedures, announced today that... 
Via MarketMinute
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance
News headline image
3 Underrated Robotics Stocks Poised for Huge Gains ↗
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
STEREOTAXIS INC (NYSEARCA:STXS) Stock Falls 9.5% After Q3 2025 Revenue Miss ↗
Stereotaxis stock fell sharply after Q3 2025 results, as a 13% revenue miss overshadowed a smaller-than-expected quarterly loss. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
A Look at Stereotaxis's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
New Robotic System Promises Faster, Safer Care For Arrhythmia Patients ↗
Stereotaxis (AMEX: STXS) announces first procedures with Genesis Robotic Magnetic Navigation System for minimally invasive endovascular interventions. 
Via Benzinga
News headline image
Earnings Scheduled For November 11, 2025 ↗
 
Via Benzinga
News headline image
Stereotaxis Inc (NYSEARCA:STXS) Q2 2025 Earnings: Revenue Surpasses Forecasts, Losses Narrower Than Expected ↗
Stereotaxis Inc (NYSE:STXS) Q2 2025 earnings beat revenue estimates with $8.8M, narrowing losses to -$0.05 EPS. Stock rose 1.83% post-announcement. 
Via Chartmill
Topics Earnings
News headline image
What's Going On With Stereotaxis Shares Wednesday? ↗
Stereotaxis shares are moving higher on Wednesday after the company announced it was accepted into the NVIDIA Connect program. 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 11, 2024 ↗
 
Via Benzinga
News headline image
STXS Stock Earnings: Stereotaxis Misses EPS, Misses Revenue for Q2 2024 ↗
STXS stock results show that Stereotaxis missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.